Package Leaflet: Information for the User
Rivaroxaban Aristo 2.5 mg film-coated tablets EFG
Read the entire package leaflet carefully before starting to take this medication, as it contains important information for you.
Contents of the Package Leaflet
You have been prescribed rivaroxaban because
Rivaroxaban reduces the risk of having another myocardial infarction in adults, or reduces the risk of death due to heart or blood vessel disease.
You will be prescribed rivaroxaban along with another medication. Your doctor will also instruct you to take:
You will be prescribed rivaroxaban along with another medication. Your doctor will also instruct you to take aspirin.
In some cases, if you are given rivaroxaban after an intervention to open a narrowed or blocked artery in your leg to restore blood flow, your doctor may also prescribe clopidogrel for you to take in addition to aspirin for a short period of time.
Rivaroxaban contains the active substance rivaroxaban, which belongs to a group of medications called antithrombotic agents. It works by blocking a coagulation factor (factor Xa) and thus reducing the tendency of blood to form clots.
Do not take Rivaroxaban
Do not take Rivaroxaban and inform your doctorif any of these circumstances apply to you.
Warnings and precautions
Consult your doctor or pharmacist before starting to take Rivaroxaban.
Rivaroxaban should not be used in combination with other medications that reduce blood coagulation, other than aspirin or clopidogrel/ticlopidine, such as prasugrel or ticagrelor.
Be careful with Rivaroxaban
Inform your doctor if you have any of these situationsbefore taking rivaroxaban. Your doctor will decide if you should be treated with this medication and if you should be kept under closer observation.
If you need surgery:
Children and adolescents
Rivaroxaban is not recommended in children and adolescents under 18 years of age.There is not enough information available on its use in children and adolescents.
Other medications and rivaroxaban
Inform your doctor or pharmacist if you are using, have recently used, or may need to use any other medication, including those obtained without a prescription.
If any of these circumstances apply to you,inform your doctorbefore taking rivaroxaban, as the effect of rivaroxaban may be increased. Your doctor will decide if you should be treated with this medication and if you should be kept under closer observation.
If your doctor considers that you have a higher risk of developing a stomach or intestinal ulcer, they may recommend that you use a preventive treatment in addition.
If any of these circumstances apply to you,inform your doctorbefore taking rivaroxaban, as the effect of rivaroxaban may be reduced. Your doctor will decide if you should be treated with Rivaroxaban and if you should be kept under closer observation.
Pregnancy and breastfeeding
Do not take rivaroxaban if you are pregnant or breastfeeding. If there is any possibility that you may become pregnant, use a reliable contraceptive while taking rivaroxaban. If you become pregnant while taking rivaroxaban, inform your doctor immediately, who will decide how you should be treated.
Driving and using machines
Rivaroxaban may cause dizziness (a common side effect) or fainting (an uncommon side effect) (see section 4, "Possible side effects"). Do not drive or use machines if you are affected by these symptoms.
Rivaroxaban contains lactose and sodium
If your doctor has told you that you have an intolerance to certain sugars, consult with them before taking this medication.
Rivaroxaban contains sodium
This medication contains less than 1 mmol of sodium (23 mg) per tablet; this is, essentially "sodium-free".
Follow the instructions for administration of this medication exactly as indicated by your doctor. If you are unsure, consult your doctor or pharmacist again.
What dose to take
The recommended dose is one 2.5 mg tablet twice a day. Take rivaroxaban at the same time every day (e.g., one tablet in the morning and one in the evening). This medication can be taken with or without food.
If you have difficulty swallowing the tablet whole, consult your doctor about other ways to take rivaroxaban. The tablet can be crushed and mixed with water or apple sauce, immediately before taking it.
If necessary, your doctor may also administer the crushed rivaroxaban tablet through a gastric tube.
You will be prescribed rivaroxaban along with another medication.
Your doctor will instruct you to take aspirin as well.
If you receive this medication after an acute coronary syndrome, your doctor may also instruct you to take clopidogrel or ticlopidine.
If you are given rivaroxaban after an intervention to open a narrowed or blocked artery in your leg to restore blood flow, your doctor may also prescribe clopidogrel for you to take in addition to aspirin for a short period of time.
Your doctor will instruct you on the dose to take (usually between 75 and 100 mg of aspirin per day, or a dose of 75 to 100 mg of aspirin plus a daily dose of 75 mg of clopidogrel or a standard daily dose of ticlopidine).
When to start treatment with rivaroxaban
Treatment with rivaroxaban after an acute coronary syndrome should be started as soon as possible, once the acute coronary syndrome has been stabilized, i.e., from 24 hours after hospital admission and at the time when parenteral anticoagulant treatment (by injection) would be discontinued.
Your doctor will instruct you on when to start treatment with rivaroxaban if you have been diagnosed with coronary artery disease or peripheral arterial disease.
The doctor will decide how long you should continue taking the treatment.
If you take more rivaroxaban than you should
Call your doctor immediately if you have taken too many rivaroxaban tablets. Taking too much rivaroxaban increases the risk of bleeding.
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicology Information Service, phone: 91 562 04 20, indicating the medication and the amount ingested.
If you forget to take rivaroxaban
Do not take more than one tablet in a single day to make up for a missed dose. If you forget to take a dose, take the next tablet at the usual time.
If you interrupt treatment with rivaroxaban
Take rivaroxaban regularly for the time indicated by your doctor.
Do not interrupt treatment with rivaroxaban without speaking to your doctor first. If you stop taking this medication, you may increase your risk of having another myocardial infarction, a stroke, or dying from a heart or blood vessel disease.
If you have any other questions about the use of this medication, ask your doctor or pharmacist.
Like all medicines, this medicine can cause adverse effects, although not all people suffer from them.
Like other similar medicines to reduce blood clot formation, rivaroxaban can cause bleeding that can endanger the patient's life. Excessive bleeding can cause a sudden drop in blood pressure (shock). In some cases, the bleeding may not be evident.
Tell your doctor immediately if you experience any of the following symptoms:
Your doctor will decide whether to keep you under closer observation or change your treatment.
The frequencies of severe allergic reactions are very rare (anaphylactic reactions, including anaphylactic shock; may affect up to 1 in 10,000 people) and uncommon (angioedema and allergic edema; may affect up to 1 in 100 people).
General list of possible adverse effects:
Frequent(may affect up to 1 in 10 people):
Uncommon(may affect up to 1 in 100 patients):
Rare(may affect up to 1 in 1,000 people):
Very Rare(may affect up to 1 in 10,000 people)
Frequency not known(frequency cannot be estimated from available data):
Reporting of adverse effects
If you experience any type of adverse effect, consult your doctor or pharmacist, even if it is a possible adverse effect that does not appear in this prospectus. You can also report them directly through the Spanish Pharmacovigilance System for Human Use Medicines: https://www.notificaram.es. By reporting adverse effects, you can contribute to providing more information on the safety of this medicine.
Keep this medicine out of sight and reach of children.
Do not use this medicine after the expiration date that appears on the packaging and on each blister after "CAD" or "EXP". The expiration date is the last day of the month indicated.
This medicine does not require special storage conditions.
Crushed tablets
Crushed tablets are stable in water or apple puree for up to 2 hours.
Medicines should not be thrown away through wastewater or household waste. Deposit the packaging and medicines you no longer need in the SIGRE point of the pharmacy. Ask your pharmacist how to dispose of the packaging and medicines you no longer need. This way, you will help protect the environment.
Composition of Rivaroxaban Aristo
Tablet core: microcrystalline cellulose, sodium croscarmellose, lactose monohydrate, hypromellose 2910, sodium lauryl sulfate, magnesium stearate. See section 2 "Rivaroxaban Aristo contains lactose and sodium".
Tablet film coating: hypromellose 2910, titanium dioxide (E 171), macrogol 400, yellow iron oxide (E 172).
Appearance of the product and package contents
Rivaroxaban Aristo 2.5 mg film-coated tablets are yellow, round, biconvex (6 mm in diameter), and have "2.5" engraved on one side and are smooth on the other.
They are presented in transparent PVC/PVDC aluminum blisters in cardboard boxes.
Boxes of 20, 28, 45, 56, or 196 film-coated tablets.
Only some package sizes may be marketed.
Marketing authorization holder and manufacturer
Marketing authorization holder
Aristo Pharma GmbH
Wallenroder Straße 8-10
13435 Berlin
Germany
Manufacturer
S.C. Labormed-Pharma S.A.
Bd. Theodor Pallady nr. 44B, sector 3
Bucharest cod 032266
Romania
Or
Saneca Pharmaceuticals a.s.
Nitrianska 100
920 27 Hlohovec
Slovakia
You can request more information about this medicine by contacting the local representative of the marketing authorization holder:
Aristo Pharma Iberia, S.L.
C/ Solana, 26
28850, Torrejón de Ardoz
Madrid, Spain
This medicine is authorized in the EEA member states and in the United Kingdom (Northern Ireland) with the following names:
Austria Rivaroxaban Aristo 2.5 mg Filmtabletten
Italy Rivaroxaban Aristo
Norway Rivaroxaban Aristo 2.5 mg film-coated tablets
Spain Rivaroxaban Aristo 2.5 mg film-coated tablets EFG
Sweden Rivaroxaban Aristo 2.5 mg film-coated tablets
Portugal Rivaroxaban Aristo
Denmark Rivaroxaban Aristo
Germany Rivaroxaban Aristo 2.5 mg Filmtabletten
United Kingdom Rivaroxaban
(Northern Ireland)
Date of the last revision of this prospectus:January 2024
Detailed information about this medicine is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es/